Journal
CANCER CELL
Volume 25, Issue 2, Pages 226-242Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2014.01.022
Keywords
-
Categories
Funding
- National Cancer Institute [R01 CA140292]
- American Cancer Society
- Starr Cancer Consortium
- Project Cupid and One Mission
- Swedish Research Council
- Swedish Cancer Society
Ask authors/readers for more resources
Cooperative dependencies between mutant oncoproteins and wild-type proteins are critical in cancer pathogenesis and therapy resistance. Although spleen tyrosine kinase (SYK) has been implicated in hematologic malignancies, it is rarely mutated. We used kinase activity profiling to identify collaborators of SYK in acute myeloid leukemia (AML) and determined that FMS-like tyrosine kinase 3 (FLT3) is transactivated by SYK via direct binding. Highly activated SYK is predominantly found in FLT3-ITD positive AML and cooperates with FLT3-ITD to activate MYC transcriptional programs. FLT3-ITD AML cells are more vulnerable to SYK suppression than FLT3 wild-type counterparts. In a FLT3-ITD in vivo model, SYK is indispensable for myeloproliferative disease (MPD) development, and SYK overexpression promotes overt transformation to AML and resistance to FLT3-ITD-targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available